{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470611857
| IUPAC_name = ''N''-[(isopropylamino)carbonyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
| image = Torasemide.svg
| image2 = Torasemide_bas.png
| USAN = Torsemide

<!--Clinical data-->
| tradename =  Demadex, Tortas
| Drugs.com = {{drugs.com|international|torasemide}}
| MedlinePlus = a601212
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = Oral, [[Intraveneous|IV]]
<!--Pharmacokinetic data-->
| bioavailability = 80-90%
| protein_bound = Highly bound (>99%).
| metabolism = Hepatic (80%)
| elimination_half-life = 3.5 hours; [[Cirrhosis]]: 7-8 hours
<!--Identifiers-->
| IUPHAR_ligand = 7312
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 56211-40-6
| ATC_prefix = C03
| ATC_suffix = CA04
| ATC_supplemental =  
| PubChem = 41781
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00214
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 38123
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = W31X2H97FB
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 9637
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00382
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1148
<!--Chemical data-->
| C=16 | H=20 | N=4 | O=3 | S=1
| molecular_weight = 348.421 g/mol
| smiles = CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cc(C)ccc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NGBFQHCMQULJNZ-UHFFFAOYSA-N
}}

'''Torasemide''' or '''torsemide''' is a [[pyridine]]-[[sulfonyl]] [[urea]] type [[loop diuretic]] mainly used in the management of [[edema]] associated with [[congestive heart failure]]. It is also used at low doses for the management of [[hypertension]]. It is marketed under the brand names Demadex, Diuver, and Examide.

Compared with other loop diuretics, torasemide has a more prolonged [[diuretic]] effect than equipotent doses of [[furosemide]] and relatively decreased [[potassium]] loss. No evidence of torasemide-induced [[ototoxicity]] has been demonstrated in humans.<ref>{{cite journal |vauthors =Dunn CJ, Fitton A, Brogden RN |title=Torasemide. An update of its pharmacological properties and therapeutic efficacy |journal=Drugs |volume=49 |issue=1 |pages=121–42 |date=January 1995 |pmid=7705212 |doi= 10.2165/00003495-199549010-00009|url=}}</ref>

Recent publications suggest improved outcomes when used for heart failure compared with furosemide.<ref>{{cite journal|pmid=24243991 | doi=10.1177/1074248413497257 | volume=19 | issue=1 | title=Diuretics: a review and update | year=2014 | journal=J. Cardiovasc. Pharmacol. Ther. | pages=5–13 | vauthors=Roush GC, Kaur R, Ernst ME}}</ref><ref>{{cite journal|pmid=25728721 | doi=10.1016/j.ahj.2014.12.009 | volume=169 | issue=3 | title=A reappraisal of loop diuretic choice in heart failure patients | pmc=4346710 | year=2015 | journal=Am. Heart J. | pages=323–33 | vauthors=Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM}}</ref><ref>{{cite journal|pmid=26704029 | pmc=4718787 | doi=10.1016/j.amjcard.2015.10.059 | volume=117 | issue=3 | title=Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial) | year=2016 | journal=Am. J. Cardiol. | pages=404–11 | vauthors=Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM}}</ref>

==References==
{{reflist}}

==External links==
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601212.html Medlineplus drug information: Torsemide (Systemic)] – information from USP DI Advice for the Patient

{{Diuretics}}

[[Category:Loop diuretics]]
[[Category:Sulfonylureas]]
[[Category:Pyridines]]
[[Category:Aromatic amines]]
[[Category:Anilines]]
[[Category:Carbonic anhydrase inhibitors]]


{{cardiovascular-drug-stub}}